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ABSTRACT
Estradiol (E2) regulates gene expression at the
transcriptional level by functioning as a ligand for
estrogen receptor alpha (ERa) and estrogen receptor
beta (ERb). E2-inducible proteins c-Myc and E2Fs are
required for optimal ERa activity and secondary
estrogen responses, respectively. We show that
E2 induces 21 microRNAs and represses seven
microRNAs in MCF-7 breast cancer cells; these
microRNAs have the potential to control 420
E2-regulated and 757 non-E2-regulated mRNAs at
the post-transcriptional level. The serine/threonine
kinase, AKT, alters E2-regulated expression of
microRNAs. E2 induced the expression of eight Let-
7 family members, miR-98 and miR-21 microRNAs;
these microRNAs reduced the levels of c-Myc and
E2F2 proteins. Dicer, a ribonuclease III enzyme
required for microRNA processing, is also an
E2-inducible gene. Several E2-regulated microRNA
genes are associated with ERa-binding sites or
located in the intragenic region of estrogen-
regulated genes. We propose that the clinical
course of ERa-positive breast cancers is dependent
on the balance between E2-regulated tumor-
suppressor microRNAs and oncogenic microRNAs.
Additionally, our studies reveal a negative-regulatory
loop controlling E2 response through microRNAs
as well as differences in E2-induced transcriptome
and proteome.
INTRODUCTION
Estradiol (E2) controls several biological processes by
functioning as a ligand for nuclear receptors estrogen
receptor alpha (ERa) and beta (ERb) (1). ERs may par-
ticipate in the genomic (transcriptional) and non-genomic
actions of E2 (1,2). The genomic action involves binding
of ERa to the regulatory regions of target genes either
directly or through protein–protein interaction. DNA-
bound ERa then recruits various co-regulatory molecules
to induce chromatin modiﬁcations that either increase or
decrease the level of target gene transcription. Several
extracellular signal activated kinases phosphorylate and
modulate ERa activity; this may be responsible for altered
E2 responses such as resistance to anti-estrogen therapy in
breast cancer (2). The major kinases that modulate ERa
activity include ERK1/2, AKT, RSK, PAK1, p38 kinase
and SRC (2–4).
A signiﬁcant number of studies so far have focused on
E2:ERa-mediated transcriptome. The eﬀect of E2 on gene
expression at post-transcriptional level is yet to be eluci-
dated. MicroRNAs are a class of evolutionarily conserved
non-coding RNAs that control gene expression at the post-
transcriptional level (5,6). They regulate gene expression
through either direct cleavage of the target mRNAs or
by translational inhibition (5,7–9). However, control of
gene expression at the level of translation by microRNAs
is cell cycle dependent (10). A highly conserved microRNA
family is predicted to target 300 mRNA species and
together aﬀect  30% of the protein-coding genes (11,12).
Cellular stress and RNA-binding proteins, which usually
bind to sequences in between microRNA-recognition sites
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(13,14). Additional functions of microRNAs include tran-
scriptional activation of genes with complementary pro-
moter sequences (15) and chromatin modiﬁcation (16,17).
RNA polymerase II enzyme transcribes the majority
of microRNA genes (a minority by polymerase III) to
produce a primary microRNA (18,19). Approximately
50% of microRNAs are transcribed from introns of
protein-coding genes while the rest are intergenic with
primary transcripts as long as 4kb (19). MicroRNA
genes usually appear in polycistronic clusters and more
than 50% are located in cancer associated genomic regions
at fragile sites (5,20). Thus, an alteration in the expression
of a single microRNA can have a profound eﬀect on
cellular physiology because of their enormous inﬂuence
on the expression of multiple genes.
Three recent reports describe microRNA-expression
patterns in breast cancer; two of these have evaluated
the expression pattern in relation to ERa, ErbB2 and
intrinsic subtypes (21–23). Overall, microRNA levels
were lower in poorly diﬀerentiated tumors compared to
well-diﬀerentiated tumors and microRNA proﬁle rather
than mRNA-expression proﬁle correlated more accurately
with cell diﬀerentiation. ERa positive breast cancers
displayed a distinct microRNA-expression proﬁle includ-
ing elevated expression of Let-7 family members of
microRNAs and miR-21 compared to ER-negative
breast cancers (21). Blenkiron et al. described
microRNA-expression proﬁles in relation to ﬁve intrinsic
subtypes (luminal A, luminal B, normal-like, HER2+ and
basal) of breast cancer (22,24,25). Luminal subtypes and
basal type breast cancers display distinct microRNA-
expression patterns (22). ERa expression and activity in
breast cancer may be regulated by a Estrogen-ERa-
microRNA-regulatory loop as mir-206 inhibits ERa
translation by binding to the 30 UTR of ERa mRNA,
whereas ERa agonists block miR-206 expression (26).
Despite enormous progress in understanding the expres-
sion pattern of microRNAs in breast cancer, regulation of
their expression in diﬀerent breast cancer subtypes is not
known. We focused on the eﬀect of E2 on microRNA
expression in breast cancer cells with two goals: (i) to
determine whether E2 regulates the expression of any of
the microRNAs expressed at higher levels in luminal type
A/ERa-positive breast cancer; and (ii) to determine
whether these E2-regulated microRNAs subsequently
control the expression of E2-regulated genes at the post-
transcriptional level. We also examined whether extracel-
lular signal activated kinases such as AKT modulate
E2-regulated microRNA expression. Results from this
study reveal a unique role for E2 in regulating the expres-
sion of luminal type A-enriched microRNAs with tumor
suppressor and oncogenic functions and the ability of
AKT to alter E2-regulated microRNA expression.
MATERIALS AND METHODS
Cell lines
MCF-7 cells containing the bicistronic vector
control (MCF-7p) or the constitutively active AKT
(MCF-7AKT) were generated by retrovirus-mediated
gene transfer and have been described previously (27).
Virus infected cells were selected using one microgram
per ml puromycin and mass culture instead of selected
clones were used to avoid clonal bias. The constitutively
active AKT1 construct with deletion of N-terminal pleck-
strin homology domain (amino acids 4–129) but addition
of myristylation signal has been described previously (3).
Cells were maintained in MEM plus 10% fetal calf serum
and one microgram per ml of puromycin. Cells were
switched to phenol red free MEM plus 5% dextran-
charcoal treated serum (CCS) for at least 4 days prior to
experiments.
MicroRNA-expression analysis
Cells were treated with the solvent ethanol or 10
 8M
E2 for 4h and RNA was prepared using the mirVana
TM
microRNA isolation kit (Ambion Inc., Austin, TX).
MicroRNA microarray and hybridization to microRNA
arrays have been described previously (28,29). Assays were
done in duplicate with RNA from two independent clones.
Since all the probes were printed twice on the microarray
in two independent blocks, four measurements were
available for every microRNA under each experimental
condition. Signal intensity of tRNA-Thr was used for
normalization between samples and relative diﬀerences
in individual microRNA expression with or without E2
treatment was then calculated. Diﬀerentially expressed
microRNAs were identiﬁed using a linear mixed eﬀect
model that describes the relationship among three factors,
including cell type, E2 treatment, probe blocks and inter-
actions between cell type and E2 treatment. The linear
mixed eﬀect model can be described as:
yi,j,k,l,n ¼  i þ  ij þ  ik þ  ijk þ ail þ bin þ "ijkln
where i, j, k, l, n represent the the microRNA, the cell
types (MCF-7p or MCF-7AKT), the conditions (with
and without E2 treatment), the RNA samples and block
on the array, respectively.  ij and  ik represent the eﬀect of
cell types and conditions, and gijk denotes the interaction
of these two factors. The RNA sample and block are
considered as random eﬀects, and the RNA sample
factor is nested in the cell type and condition factors.
E2-induced changes in Let-7f, miR-98 and miR-21
was veriﬁed in four independent RNA preparations by
quantitative reverse transcription polymerase chain reac-
tion (qRT-PCR) using The TaqMan microRNA assays
designed to detect and accurately quantify mature
microRNAs (Applied Biosystems, Foster City, CA).
Primers speciﬁc to small RNA, RNU66, were used for
normalization (Applied Biosciences). Target genes of dif-
ferentially expressed microRNAs were predicted using
TargetScan (12).
Locked nucleic acid (LNA) treatment and western
blot analysis
LNA against Let-7f, miR-98 and miR-21 as well as
control LNA were obtained from Exiqon, Inc (Woburn,
MA). LNA (5nM) was transfected into cells grown in
60mm plates using Lipofectamine reagent (Invitrogen,
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60-mm plates. E2 or ethanol was added to cells 24h
after splitting and harvested for western analysis 24h
post E2 treatment. All experiments were done three to
ﬁve times with similar results. Antibodies against AIB1
(BD biosciences, San Jose, CA), E2F1, E2F2, Maspin
(Santa Cruz Biotechnology, Santa Cruz, CA), c-Myc
(Upstate Biotechnology, Lake Placid, NY), EZH2 (Cell
Signaling, Danvers, MA) and PDCD4 (Abcom, Cam-
bridge, MA) were used for western analysis as per instruc-
tions of manufacturers.
Total RNA isolation, northern blotting and quantitative
reverse transcription polymerase chain reaction (qRT–PCR)
Total RNA from ethanol and E2-treated cells was isolated
using an RNeasy kit from Qiagen (Valencia, CA). North-
ern blotting was performed as described previously (3).
RNA was reverse transcribed using a single-stranded
cDNA synthesis kit (Invitrogen, Carlsbad, CA) and sub-
jected to quantitative polymerase chain reaction (Q-PCR)
using Syber green (Applied Biosciences, Foster City, CA).
Primers used were: Dicer forward primer TCACCTGCCT
CACTTGACCTGAAA; Dicer reverse CGCTTTCAAAC
TGCTGCTCAT; beta-actin forward TGGATCAGCAA
GCAG; and beta-actin reverse GCATTTGCGGTGGAC.
Chromatin immunoprecipitation assay
The entire ERa chromatin immunoprecipitation-microar-
ray (ChIP-on-chip) data set of MCF-7p and MCF-7AKT
cells as well as statistical analysis has been described (27).
ERa ChIP assay was performed as described previously
(30). ChIP DNA was subjected to Q-PCR using the
primers 50-TCTTTGACCCACTAGCCTTGCAGT-30
and50-TCACTTCTCTCTGGGCCACAGTTT-30todeter-
mine E2-inducible changes in ERa binding to the central-
binding site close to miR-21 identiﬁed in ChIP-on-chip.
The chromosomal location of ERa binding was deter-
mined using UCSC genome browser (www.genome.ucsc
.edu). E2-inducible changes in ERa binding were not
detected with ChIP DNA obtained by immunoprecipita-
tion with control IgG.
Transient transfection and luciferase assay
The 30 untranslated regions of AIB1 (nucleotides
6872–7145 of NM_181659) or c-Myc (nucleotides 1861–
2360 of NM_002467) were cloned into a cytomegalovirus
(CMV) enhancer-promoter driven luciferase gene at the 30-
end of the coding sequence. MCF-7 cells maintained in
MEM plus 5% CCS were transfected with the above plas-
mid and the internal control plasmid renila luciferase
using lipofectamine (Invitrogen). E2 was added 24h
after transfection and luciferase assay was performed
16h after E2 addition using dual luciferase assay kit
from Promega (Madison, WI).
RESULTS
E2 regulates the expression of microRNAs
We recently reported the ERa-binding pattern in MCF-7
cells with a retrovirus vector control (MCF-7p) and
MCF-7 cells overexpressing constitutively active AKT1
(MCF-7AKT) (27). We observed ERa-binding sites asso-
ciated with 1667 and 1908 genes in one-hour E2-treated
MCF-7p and MCF-7AKT cells, respectively. However,
not all of the genes with ERa-binding sites had an
altered transcript level after E2 treatment. Also, not all
E2-regulated genes, as identiﬁed by microarray analysis
of both cell types with or without E2 treatment for 4h,
contained ERa-binding sites suggesting that there are
other mechanisms by which E2 regulates gene expression.
In fact, among 833 E2-regulated genes in MCF-7p cells,
only 299 genes contained ERa-binding sites (see Supple-
mentary Data for select genes). Although secondary estro-
gen response through E2-regulated transcription factors
such as E2F1/2 can explain the lack of correlation between
ERa binding and target gene expression (31), control of
gene expression by E2-regulated microRNAs has not
been investigated in detail. To investigate this possibility,
we determined microRNA-expression patterns in MCF-7p
and MCF-7AKT cells with and without E2 treatment for
4h. We observed 21 E2-inducible and 7 E2-repressible
microRNAs in MCF-7p cells (statistical cutoﬀ P-value
<0.05 and fold change >1.5 or <0.7) (Table 1).
E2 increased the expression of eight members of the
Let-7 family microRNAs ( 2.2-fold increase), which pre-
viously have been shown to be overexpressed in luminal
type A breast cancer (21,22). Similarly, E2 increased the
expression of miR-21, which is also expressed at a higher
level in luminal type-A breast cancer. AKT completely
changed the pattern of E2 regulation of microRNA
expression. In MCF-7AKT cells, E2 increased the expres-
sion of only one microRNA but reduced the expression of
20 microRNA species. Basal expression of 11 microRNAs
was lower in MCF-7AKT cells compared to MCF-7p
cells; whereas, one microRNA displayed elevated expres-
sion in MCF-7AKT cells. Seven of the microRNAs that
displayed lower basal expression in MCF-7AKT cells were
E2-inducible in MCF-7p cells. Only three microRNAs
(miR-143, miR-506 and miR-98) showed similar
E2-dependent regulation in both cell types.
We performed microRNA qRT–PCR, which quantita-
tively measures only mature microRNAs, to conﬁrm
E2-inducible expression of Let7f, miR-21 and miR-98
(Figure 1A). Consistent with the microarray results, E2
increased the expression of these microRNAs in MCF-
7p cells; none of the E2-induced changes in microRNA
expression in MCF-7AKT cells was statistically signiﬁ-
cant. E2 increased the expression of all three of these
microRNAs in parental MCF-7 cells that were used to
generate the above cell lines (Figure 1B, top panel). E2
similarly increased Let-7f, miR-98 and miR-21 levels in
T47-D cells, another ERa-positive cell line (Figure 1B,
middle panel). Interestingly, in BT-474, an ERa-positive/
HER2-positive cell line, E2-inducible expression of these
microRNAs was modest (Figure 1B, bottom panel).
To determine the requirement of ERa for E2-regulated
expression of the above microRNAs, we pretreated
MCF-7 cells with fulvestrant for 24h and then stimulated
cells with E2 for 4h. Fulvestrant inhibits ERa function
through degradation. The basal levels of miR-98 and
miR-21 microRNAs were elevated in fulvestrant-treated
4852 Nucleic Acids Research, 2009, Vol. 37,No. 14cells and were only marginally increased upon
E2-treatment (Figure 1C). The basal level of Let-7f was
marginally increased but it did not reach statistical signif-
icance. These results suggest that the unliganded ERa
represses the expression of these microRNAs and E2
relieves this repression, which is consistent with a recent
report on nuclear receptor-mediated microRNA regula-
tion in Caenorhabditis elegans (32).
Putative targets of E2-regulated microRNAs
E2-inducible expression of Let-7 family members and
reduced basal and/or E2-inducible expression of this
family in MCF-7AKT cells is interesting because reduced
expression of this family is linked to loss of diﬀerentiation
and increased self-renewal of progenitor cells (33,34). Both
Let-7 family members and miR-98 have the same seed
sequence and target the same mRNAs. Ras family onco-
genes and HMGA2 are the well-characterized targets of
Let-7 (35,36). c-Myc is also a target of Let-7 (37) and miR-
21 (38). Based on TargetScan and miRGen analyses, E2F1
and E2F2, E2-inducible transcription factors involved in
secondary estrogen responses (31), are predicted targets of
miR-205 and Let7/miR-98, respectively. E2F1 and E2F2
are also targets of miR20 (39); mir-20b is expressed at a
higher level in MCF-7p cells compared to MCF-7AKT
cells (Table 1). NCOA3/AIB1 is a target of miR-17-5p
(40), which in our studies is E2-inducible microRNA
(Table 1). EZH2 is a multifunctional protein that inte-
grates Wnt and E2 signaling in breast cancer cells and
the abnormal function of this protein is linked to several
diseases (41). Based on TargetScan analysis, EZH2 is a
likely target of mir-124a and mir-506, both of which are
repressed by E2. The above genes thus constituted poten-
tial targets of E2-regulated microRNAs.
We focused our studies only to those genes that are
involved in E2-signaling pathways and/or regulated
by E2 at the transcriptional level and additionally con-
trolled at the post-transcriptional level by E2-regulated
microRNAs as part of an autoregulatory loop
(Figure 2A). We observed repression of AIB1 and induc-
tion of EZH2 by E2 in both cell types. Additionally, while
E2F1 and E2F2 displayed a delayed E2-inducible increase
in protein levels in MCF-7p cells, basal levels of both of
these proteins were elevated with a further E2-inducible
increase in MCF-7AKT cells. Elevated basal levels of
these two proteins in MCF-7AKT cells correlate with a
lower level of miR20b in these cells compared to MCF-7p
cells (Table 1). Previously, we reported little diﬀerence in
the kinetics of E2-inducible expression of c-Myc mRNA in
parental and CA-AKT overexpressing MCF-7 cells (3).
However, at the protein level, E2-mediated increase in
c-Myc is advanced in MCF-7AKT cells compared to
MCF-7p cells (Figure 2A). None of the previous micro-
array proﬁling studies including our study observed an
eﬀect of E2 on EZH2 mRNA level and our ChIP-chip
data did not identify ERa-binding sites associated with
the EZH2 gene. Furthermore, RT–PCR analysis has con-
ﬁrmed the lack of an E2 eﬀect on the mRNA levels of
EZH2 (data not shown). Thus, E2 may control translation
of AIB1 and EZH2 through microRNAs.
Table 1. The eﬀect of E2 on microRNA expression in MCF-7p and
MCF-7AKT cells
MCF-7p cells MCF-7AKT cells
Name Fold
change
Name Fold
change
E2-inducible microRNAs
miR-Let-7f 3.2 miR-520d 4.8
miR-Let-7a 2.9
miR-Let-7d 2.7
miR-Let-7c 2.6
mir-Let-7g 2.6
miR-203 2.4
miR-Let-7b 2.3
miR-Let-7e 2.2
miR-98 2.1
miR-21 2.0
miR-200a 2.0
miR-103 1.8
miR-200c 1.8
miR-107 1.7
miR-17-5p 1.7
miR-23a 1.6
miR-200b 1.6
miR-30c 1.6
miR-30b 1.5
miR-424 1.5
miR-let7i 1.5
E2-repressible microRNAs
miR-302b
  0.4 miR-524 0.3
miR-506 0.5 miR-518d 0.3
miR-524
  0.5 miR-518e 0.3
miR-27a 0.6 miR-506 0.3
miR-27b 0.6 miR-409-5p 0.3
miR-143 0.6 miR-216 0.3
miR-9 0.7 miR-518c
  0.5
miR-526b 0.5
miR-34b 0.5
miR-337 0.5
miR-146 0.5
miR-128b 0.5
miR-124a 0.5
miR-211 0.6
miR-143 0.6
miR-128a 0.6
miR-126
  0.6
miR-126 0.6
miR-1 0.6
miR-10b 0.7
MicroRNAs that display diﬀerences in basal expression
between two cell types
a
miR-520d 5.1 miR-200a 0.6
miR-let7g 0.5 miR-182 0.6
miR-337 0.5 miR-17-5p 0.6
miR-20b 0.5 miR-1 0.6
miR-Let-7i 0.6 miR-203 0.6
miR-98 0.6 miR-200c 0.7
Cells were treated with E2 for 4h and microRNA expression array
analysis was performed. Only those microRNA whose expression dif-
ferences with a P-value of <0.05 among untreated and E2-treated cells
are presented. miR-98 was induced by E2 in both cell types (2.1-fold in
MCF-7p cells, 1.4-fold in MCF-7AKT cells) whereas miR-143 (to same
level) and miR-506 (0.50 in MCF-7p cells and 0.30 in MCF-7AKT
cells) were repressed by E2 in both cell types.
aMicroRNA with fold change >1 is expressed at higher levels in MCF-
7AKT cells, whereas fold change <1 represent microRNAs expressed at
higher levels in MCF-7p cells.
Nucleic Acids Research, 2009,Vol.37, No. 14 4853The 30 UTRs of mRNAs are considered to be the
primary targets of microRNAs although recent studies
indicate the coding sequences are also targeted (8,9).
We cloned the predicted microRNA target sequences
in the 30 UTR of AIB1 and c-Myc into a CMV-driven
luciferase-reporter vector and investigated the eﬀects of
E2 on luciferase levels (Figure 2B). E2 did not have
an eﬀect on luciferase expression in cells transfected
with parental vector. In contrast, E2-reduced luciferase
expression in cells transfected with vectors containing
either the AIB1 or c-Myc 30 UTR. These results suggest
that the 30 UTR of AIB-1 and c-Myc genes contain
sequences that are targeted by E2-regulated microRNAs.
Note that based on ChIP-on-chip data, cloned 30-UTR
sequences of both AIB1 and c-Myc lack ERa-binding
sites (27).
Figure 1. (A) E2-inducible expression of Let-7f, miR98 and miR-21 in MCF-7p and MCF-7AKT cells. MCF-7p and MCF-7AKT cells were
treated with E2 (10
 8M) for indicated time and microRNA was subjected qRT–PCR. RNU66, small RNAs encoded in the intron of RPL5 gene
(chr1:93018360–93018429) was used for normalization between samples. Mean plus standard error of the mean (SEM) are shown.
 P<0.03,
ethanol versus 1-h E2-treated cells;
  P<0.001 ethanol versus 4h E2-treated cells. (B) The eﬀect of E2 on the expression of Let-7f, miR-98 and
miR-21 in MCF-7 (top), T47-D (middle) and BT-474 (bottom) cells. (C) The eﬀect of fulvestrant treatment on basal and E2-regulated expression
of Let-7f, miR-98 and miR-21. Cells were pretreated with 100nM fulvestrant for 24h and then treated with E2 for 4h.
 P<0.05, ethanol versus
E2-treated;
  P<0.05, ethanol versus fulvestrant treated cells.
4854 Nucleic Acids Research, 2009, Vol. 37,No. 14Let-7f/miR-98 and miR-21 may be part of
negative-regulatory loop that control E2-induced
levels of c-Myc, E2F1 and E2F2 proteins
Our previous studies have shown E2-mediated increase in
mRNA levels of c-Myc, E2F1 and E2F2 in MCF-7p and
MCF-7AKT cells (3,27). We used LNA-mediated knock-
down of Let-7f/miR98 to determine whether reducing the
levels of these microRNAs lead to changes in E2-inducible
expression of c-Myc, E2F1 and E2F2 at the protein level.
Neither LNA against Let-7f/miR-98 nor LNA against
Figure 2. Putative targets of E2-induced microRNAs. (A) MCF-7p and MCF-7AKT cells were treated with E2 for indicated time and western
blotting was performed. (B)3 0-UTR of AIB1 or c-Myc reduces E2-inducible expression of a luciferase reporter under the control of CMV enhancer-
promoter. MCF-7 cells were transfected with indicated reporters along with the internal control Renila-luciferase under TK promoter-enhancer and
luciferase activity was measured in untreated and E2-treated cells.
 P<0.05, ethanol treated versus E2-treated cells. (C) LNA against Let-7f/miR-98
and miR-21 diﬀerentially aﬀect basal and E2-inducible levels of c-Myc and E2F2 proteins in MCF-7p cells. Cells were treated with control or speciﬁc
LNA and treated with E2 for 24h. Western blot analysis was done with indicated antibodies. (D) Expression levels of E2F-1, E2F-2, c-Myc and
AIB1 from three to ﬁve independent experiments, as measured by densitometric scanning (Mean plus SEM), are indicated.
 P<0.05, ethanol versus
E2-treated cells;
  P<0.05, control LNA treated versus Let-7f/mir-98 or miR-21 LNA-treated cells. Note the eﬀects of LNA against Let-7f/miR98
and miR-21 on E2F2 and c-Myc but not on E2F1 and AIB1 protein levels.
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(Figure 2C and D). Consistent with TargetScan predic-
tion, LNA against Let7f/miR-98 increased E2-inducible
levels of E2F2. Surprisingly, basal level of E2F2 was
also increased in miR-21 LNA treated MCF-7p cells com-
pared to control LNA-treated cells. LNA against Let-7f/
miR-98 but not miR-21 increased the basal levels of c-Myc
proteins. LNA against Let-7f or miR-98 individually was
ineﬀective, possibly due to their redundant targets (data
not shown). E2 mediated reduction of AIB1 protein levels
was unaﬀected by LNA against Let-7f/miR-98 or miR-21
(Figure 2C and D). Thus, E2-induced Let7f/miR-98
controls the expression levels of expected targets (E2F2
and c-Myc), whereas miR-21 unexpectedly controls the
expression of E2F2. Also, the overall protein level changes
(1.5–2-fold) that we observed in cells transfected with
LNA-targeting speciﬁc microRNAs are within the range
predicted and veriﬁed by proteomic approaches (11,42).
Bioinformatics analysis of potential targets of E2-regulated
microRNAs identify additional E2-responsive genes
We then investigated whether any luminal type A speciﬁc
genes expressed in primary breast cancers are putative
targets of E2-regulated microRNAs using available bioin-
formatics tools. We used TargetScan among several avail-
able search engines because this program is more robust
with regards to its prediction algorithm and several of its
predictions have been veriﬁed by proteomics (11,42).
Indeed, major genes that deﬁne a luminal type A pheno-
type or are overexpressed in luminal type A breast cancers
including FOXA1, GATA-3, ERa and MyB are putative
targets of E2-regulated microRNAs (Supplementary
Table S1).
We next determined whether any of the E2-regulated
mRNAs are the targets of E2-regulated microRNAs. The
21 E2-induced microRNAs in MCF7p cells belong to 10
distinct microRNA families. We analyzed whether these
microRNAs-target genes that are induced or repressed by
E2 in MCF-7 cells. Results of microarray analysis of
untreated and 4h E2-treated MCF-7p and MCF-7AKT
cells were used for this purpose (27). E2-induced
microRNAs are predicted to target 94 E2-inducible, 142
E2-repressible and 541 non-E2-regulated mRNAs in
MCF-7 cells. Detailed statistical analysis is presented in
Table 2. Supplementary Table S2 contains name of these
genes, E2-dependent changes in their mRNA levels after
4h of E2 treatment in both cell types, and microRNAs
that may target them. MicroRNAs repressed by E2,
which belongs to four families (hsa-miR-302b
  and hsa-
miR-524
  are excluded from this analysis due to the lack
of prediction from TargetScan), are predicted to target 67
E2-inducible, 116 repressed and 407 non-E2-regulated
genes. Supplementary Table S2 contains names and
E2-regulated expression of these genes. Taken together,
E2-regulated microRNAs potentially target 1021 genes
in MCF-7p cells. Similar analysis in MCF-7AKT cells
showed that microRNAs upregulated by E2 in these cells
may target 20 E2-inducible genes, 20 E2-repressed genes
and 68 non-E2-regulated genes. MicroRNAs repressed
by E2 in these cells may target 148 E2-inducible genes,
111 E2-repressed genes and 554 non-E2 target genes
(Table 2 and Supplementary Table S3). Overall,
E2-regulated microRNAs potentially control 850 genes in
MCF-7AKT cells.
miR-21-regulatory region is associated with
ERa-binding sites
We used our ChIP-on-chip data set (27) and other bioin-
formatics tools to investigate how E2 regulates the expres-
sion of microRNAs. MicroRNAs can be transcribed as
independent units or as parts of intronic sequences in
large transcribed genes (19). MicroRNAs that reside in
the intergenic sequence are transcribed as 3–5-kb tran-
scripts with clearly deﬁned 50 and 30 boundaries. The
promoter/enhancer regions of such microRNA genes are
enriched for ﬁve transcription factor-binding sites:
MSX-1, TLX2 (Hox11L1), CDC5, SRF and ZNF238
(19). Table 3 provides summary of E2-regulated
microRNAs that are associated with ERa-binding sites
in their regulatory region or located in the intronic
region of known E2-regulated genes. An ERa-binding
site was assigned to a microRNA if it is located within
20kb of the 50 transcription start site or within 20-kb
of the 30 transcription termination site (27). Additional
details of ERa-binding site distribution around
microRNAs that are regulated by E2 in MCF-7p and
MCF-7AKT cells or ERa-binding sites along with
E2-regulated expression of host genes that harbor these
microRNAs are provided as supplementary ﬁles (Supple-
mentary Table S4 and Supplementary Table S5).
We further evaluated ERa binding to miR-21-
regulatory regions by ChIP assay. Location of the
miR-21 transcribed region in relation to ERa-binding
sites and results of the ChIP assay conﬁrming ERa bind-
ing are shown in Figure 3. Unliganded ERa bound to
three regions in MCF-7p cells (Figure 3A). E2 reduced
Table 2. Number of genes potentially targeted by E2-regulated microRNAs in MCF-7p and MCF-7AKT cells
mRNAs induced
by E2 (FC>1.5)
mRNAs repressed
by E2 (FC 1.5)
Non-E2-regulated
mRNAs ( 1.5<FC<1.5)
E2 upregulated microRNA targets in MCF-7p cells 94 142 541
E2 downregulated microRNA targets in MCF-7p cells 67 116 407
E2 upregulated microRNA targets in MCF-7AKT cells 20 20 68
E2 downregulated microRNA targets in MCF-7AKT cells 148 111 554
Cellular mRNAs are subclassiﬁed into E2-induced, E2-repressed and unaﬀected by E2 but expressed in MCF-7p and MCF-7AKT cells based
microarray analysis of ethanol or E2 (4-h) treated cells (27). FC=Fold change.
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conﬁrm ERa binding to the region II (central region).
Unliganded ERa binding to this region was observed in
MCF-7p cells (10-fold higher levels of PCR product com-
pared to IgG control), which was unaﬀected upon E2
treatment (Figure 3B). However, ERa binding to this
region was enhanced by E2 in MCF-7AKT cells. Thus,
the miR-21 gene is associated with an authentic ERa-
binding site. The fact that E2 reduced the number of
miR-21 associated ERa-binding sites in MCF-7p cells
and that this reduction in binding correlates with induc-
tion of miR-21 suggests that unliganded ERa suppresses
the expression of this microRNA and E2 relieves that
repression. This observation is consistent with data pres-
ented in Figure 1C and recent observations in C. elegans
(32). In summation, our studies reveal a complex
mechanism of E2-mediated changes in microRNA expres-
sion and the consequences of these changes on post-
transcriptional control of gene expression.
Dicer is an E2-inducible gene
To determine whether E2 controls microRNA processing,
we searched our ChIP-on-chip datasets and microarray
datasets of untreated and E2-treated MCF-7p and
MCF-7AKT for ERa binding and E2-regulated expres-
sion of genes associated with microRNA processing (27).
The only gene associated with an ERa-binding site is
Dicer (Figure 4A) and Dicer mRNA was induced by E2
as measured by northern analysis and qRT–PCR
(Figure 4B). AKT only delayed E2-mediated induction
of Dicer. These results suggest that E2 regulates
microRNA machinery at the level of transcription as
well as processing.
DISCUSSION
Deregulation of microRNA expression is observed in var-
ious diseases including cancer, cardiovascular diseases
and neurodegenerative disorders (43,44). While biological
functions of microRNAs are being studied extensively,
signaling pathways that control their expression are just
beginning to be explored. Cytokines and hypoxia are
known modulators of microRNA expression (45,46). In
this study, we investigated the role of E2 in modulating
microRNA expression in breast cancer cells. Unlike the
eﬀect of E2 on mRNA-encoding genes where the majority
of them are repressed (47), 21 of the 28 E2-regulated
microRNAs are induced. Our results on E2-regulated
expression of miR-21 diﬀer from a publication that
appeared in this journal during revision of our manu-
script (48). Wickramasinghe et al. (48) found lower miR-
21 expression in MCF-7 but not T47-D cells treated
with E2 for 6h compared to untreated cells and this
E2-mediated downregulation of miR-21 correlated with
elevated expression of several miR-21 target genes.
Reasons for this discrepancy are unknown. However, we
note that there are several variants of MCF-7 and we have
previously shown that these variants express diﬀerent
levels of co-activators involved in ERa-mediated gene
expression (49). The second possibility is that E2 regulates
miR-21 in a biphasic manner (induction followed by
repression), which helps in ﬁne-tuning of the E2 response.
We also note that E2-mediated upregulation of miR-21
observed in our study correlates with reported higher
levels of miR-21 expression in primary ERa+ breast
cancers (21).
Possible mechanisms of E2-regulated expression
of microRNAs
Based on the results of our ChIP-on-chip study and micro-
array expression analysis (27), at least three distinct
mechanisms appear to be involved in E2-mediated upre-
gulation of microRNAs. First is the direct binding of ERa
to the regulatory regions of microRNAs. The regulatory
regions of miR-21 and miR-23a contain ERa-binding
sites. With respect to miR-21, unliganded ERa binds to
three regions in MCF-7p cells but only one region in
MCF-7AKT cells. E2 either enhances or decreases inter-
action of ERa to the region shared by both cell types,
depending on AKT activity. How this unusual interaction
pattern of ERa to the miR-21-regulatory region impacts
the expression of this microRNA is unknown.
The second mechanism of E2-regulated microRNA
expression may involve E2-inducible expression of
mRNA-encoding genes that harbor microRNA genes
in their intronic regions. NF-YC and C21orf34 are
repressed by E2 (5) yet microRNAs within their introns
are induced by E2. It remains to be determined whether
these microRNAs are transcribed from an intronic
promoter independent of the host gene. The third possi-
bility is that E2 regulates the expression of transcription
factors that control the expression of microRNAs. In
this respect, TRANSFAC database analysis revealed
selective enrichment of binding sites for MRF-2, PBX-1,
RUNX1, RUNX2 and GATA-3-transcription factors in
Table 3. E2-regulated microRNAs associated with ERa-binding sites or
located in the intragenic region of E2-regulated genes
MicroRNA Fold change in
microRNA expression
after E2 treatment in
MCF-7p cells
ERa-binding sites
after E2 treatment
MicroRNAs with ERa-binding sites
miR-21 1.98 1
miR-23a 1.62 4
miR27a 0.64 4
miR27b 0.60 5
MicroRNA Fold change in
microRNA levels
after E2 treatment
of MCF-7p cells
Host gene E2 eﬀect on
the host gene
MicroRNAs located in the intragenic regions of E2-regulated genes
miR30c 1.58 NF-YC  1.2
miR-9 0.654 C1orf61 1.16
Let-7c 2.6 C21orf34  1.9
Let-7g 2.6 TMEM113 1.3
miR-27b is located within aminopeptidase gene, which is an
E2-inducible gene and displayed ﬁve and eight ERa-binding sites in
E2-treated MCF-7p and MCF-7AKT cells, respectively.
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quent validation by qRT–PCR revealed MSX1, RUNX1
and RUNX2 as E2-inducible genes and MRF-2 and PBX-
1 as E2-repressible genes in MCF-7 cells (data not shown).
Previous studies have shown E2-regulated expression of
GATA-3 in breast cancer cells (50). Which of these tran-
scription factors contribute to E2-dependent microRNA
expression remains to be addressed.
The fact that eight members of the Let-7 family are
induced by E2 is interesting and suggests that a common
pathway is involved in the expression and/or processing of
Let-7 family microRNAs. This pathway is under the con-
trol of E2. In this respect, LIN28 has been shown to sup-
press the processing of all Let-7 family microRNAs
without interfering with processing of other microRNAs
(51). However, neither LIN28a nor LIN28b has ERa-
binding sites and our microarray studies and RT–PCR
analysis indicate lack of E2-regulated LIN28 expression.
We cannot rule out a post-translational activation mech-
anism of LIN28 by E2-regulated signaling pathways,
which may induce enhanced processing of Let-7 family
members. Among the several genes studied that are
known to be involved in the processing of microRNAs,
only Dicer is associated with ERa-binding sites and is
induced by E2 (Figure 4). Oncomine database analysis
revealed overexpression of Dicer in ERa-positive breast
cancers compared to ERa-negative breast cancers, which
is consistent with our results of E2-regulated expression of
this gene. Thus, E2 not only regulates the expression of
speciﬁc microRNAs, but also may have global eﬀects on
microRNA-regulated gene expression by altering their
rate of processing.
Among the microRNAs repressed by E2, only miR-27a
and mir-27b contain ERa-binding sites. E2 may indirectly
Figure 3. The regulatory regions of miR-21 contain ERa-binding sites. (A)E R a DNA-binding patterns to the genomic region harboring miR-21 gene
on chromosome 17. Black bars represent ERa-binding sites in two cell types observed under ethanol and E2-treated condition. (B) ChIP analysis of
ERa binding to the genomic region (central bar) shown in A. ChIP DNA obtained with ERa antibody was subjected to semi-quantitative PCR (top)
or Q-PCR (bottom) with speciﬁc primers and relative enrichment of ERa binding is shown after normalizing ERa binding in ethanol MCF-7p or
MCF-7AKT cells to one unit. The level of ERa binding in E2-treated MCF-7AKT cells was signiﬁcantly higher than in untreated cells.
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transcriptional repressor. In this respect, c-Myc has been
shown to be a global repressor of microRNA expression
(52). c-Myc is an E2-inducible gene, which is further neg-
atively regulated by E2-induced Let-7 (Figure 2). Let-7
directly represses c-Myc translation and also destabilizes
c-Myc transcript levels by inhibiting translation of IMP-1,
a RNA-binding protein that stabilizes c-Myc transcripts
(37,53). Thus, pathways that disrupt the ﬁnely balanced
positive and negative eﬀects of E2 on c-Myc expression
may play a signiﬁcant role in breast cancer progression.
The global eﬀect of AKT on E2-regulated microRNA
expression is puzzling and may involve AKT-dependent
changes in the activity of transcription factors. The failure
of E2 to induce the expression of miR-200a, miR-17-5p,
miR-200a, miR-200c and miR-203 in MCF-7AKT cells
could be due to AKT-mediated downregulation of the
basal expression of these microRNAs and the eﬀect of
E2 on them being below the detection level in our assay
(Table 1). miR-520d appears to be an exception to the
general phenomena of AKT-dependent decrease in
microRNA expression as AKT increased the basal levels
of this microRNA by  5-fold and this microRNA was
further induced by E2 in AKT overexpressing cells.
miR-520d may be E2-inducible in parental cells also but
its expression is below the level for detection. The signif-
icance of AKT-mediated induction of miR-520d could not
be predicted as targets of this microRNA are yet to be
identiﬁed.
Potential role of E2-regulated microRNAs in breast cancer
The majority of E2-regulated microRNAs appear to have
a tumor suppressor role by participating in a negative
feedback loop to restrict E2 action. For example,
E2-inducible expression of Let-7 family members may
limit the expression of Ras and c-Myc oncogene levels
and promote diﬀerentiation of cancer cells. Control of
c-Myc levels by Let-7 is particularly relevant to E2 signal-
ing because c-Myc cooperates with ERa in the expression
of select target genes and Let-7 may play a role in attenu-
ating such cooperative gene expression (54). E2-induced
microRNAs may control secondary estrogen responses by
limiting the expression levels of E2F family members (31).
Additionally, E2-induced microRNA miR-17-5p may
control ERa primary responses by reducing the levels of
the AIB1 coactivator (40). Figure 5 schematically repre-
sents how E2-regulated microRNAs may control E2
responses by targeting c-Myc and E2F2.
E2-regulated miR-21 may have dual roles in cancer.
It may protect cancer cells against cell death and promote
metastasis: this eﬀect of miR-21 is likely due to transla-
tional repression of pro-apoptotic PDCD4 and metastasis
suppressor Maspin (55). In this respect, overexpression of
miR-21 in MCF-7 cells leads to enhanced tumor growth in
nude mice (56). On the other hand, miR-21 may reduce
self-renewal of cancer cells with stem-cell-like properties
by inhibiting the translation of stem cell renewal genes
Oct-4, c-Myc, Nanog and Sox2 (38). For unknown
reasons, we did not observe an eﬀect of LNA against
miR-21 on PDCD4 expression in E2-treated MCF-7
cells and these cells do not express Maspin (data not
Figure 4. Dicer is an E2-inducible gene. (A)E R a DNA-binding
patterns to the genomic region harboring Dicer. Black bars represent
ERa-binding sites in two cell types observed under ethanol-treated or
E2-treated condition. (B) E2-inducible expression of Dicer in MCF-7p
and MCF-7AKT cells was measured by northern blotting (top panel).
The same blot was reprobed with 36B4 to ensure integrity of RNA.
qRT–PCR conﬁrming E2-inducible expression of Dicer is also shown
(mean plus SEM, bottom panel).
 P<0.04 ethanol-treated versus E2-
treated cells.
Figure 5. A model depicting the possible eﬀects of E2-regulated
microRNAs on E2 response and diﬀerentiated phenotype of ERa-posi-
tive breast cancer cells.
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et al. (48) with respect to PDCD4 possibly reﬂecting dif-
ferences in the variants of MCF-7 cells used in the two
studies. In our MCF-7 cells, PDCD4 is an E2-inducible
gene and is associated with ERa-binding sites. Addition-
ally, based on TargetScan prediction, PDCD4 is a target
of E2-inducible miR-200a (Table 1 and Supplementary
Table S1). Therefore, these multiple levels of E2 action
may have obscured the eﬀects of miR-21 LNA on
PDCD4 protein levels in E2-treated cells.
AKT is a major signaling molecule in breast cancer.
MMTV-AKT1 transgenic mice develop ERa-positive
breast cancer when exposed to chemical carcinogens sug-
gesting a signiﬁcant crosstalk between AKT and ERa in
breast cancer (57). The extent to which this crosstalk relies
on modulation of microRNA expression is not known
and may potentially provide important clues into the ini-
tiation of ERa-positive breast cancers. AKT decreased
E2-inducible expression of both tumor suppressor and
oncogenic microRNAs. E2-dependent reduction of miR-
126 in only AKT overexpressing cells is relevant to breast
cancer as this microRNA is considered both a tumor sup-
pressor and metastasis inhibitor (58).
In summary, we show the eﬀects of E2 on modulating
the microRNA-expression pattern as well as the potential
for extracellular signal activated kinases to modulate this
action of E2. With respect to breast cancer, our observa-
tions may have implications on responses to endocrine
therapy as signaling pathways that modulate ERa func-
tion may change the balance between tumor suppressor
and oncogenic microRNAs induced by E2 and thus alter
the response to anti-estrogen therapy.
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